The significant suppression of disease progression observed in mice with RA following treatment with CB provides strong validation for the concept of targeting CXCR4 using CB-like molecules as a potential therapeutic strategy for arthritic conditions. The gene discussed is CXCR4; the disease is rheumatoid arthritis.